Operating Cash Flow per Share: A measure of financial performance calculated as operating cash flow, expressed on a per share basis. Calculated as: Cash Flow from Operations / Weighted Average Shares Outstanding (Diluted)
Lineage Cell Therapeutics, Inc. (LCTX) had Operating Cash Flow per Share of $-0.06 for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
$1.07M |
|
$1.48M |
|
-- |
|
$1.07M |
|
$9.99M |
|
$-8.92M |
|
$10.47M |
|
$1.54M |
|
$1.54M |
|
$1.54M |
|
$1.54M |
|
$1.54M |
|
$1.54M |
|
$-8.92M |
|
$-8.68M |
|
249.50M |
|
261.47M |
|
$0.01 |
|
$-0.03 |
|
| Balance Sheet Financials | |
$52.97M |
|
$2.52M |
|
$53.25M |
|
$106.22M |
|
$8.02M |
|
$0.01M |
|
$38.41M |
|
$46.42M |
|
$59.80M |
|
$17.43M |
|
$59.80M |
|
252.91M |
|
| Cash Flow Statement Financials | |
$-15.32M |
|
$1.63M |
|
$10.03M |
|
$41.32M |
|
$37.92M |
|
$-3.41M |
|
$2.77M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
6.61 |
|
-- |
|
-- |
|
0.00 |
|
0.00 |
|
100.00% |
|
-834.71% |
|
-834.71% |
|
-- |
|
144.43% |
|
138.63% |
|
$-15.48M |
|
-- |
|
-- |
|
-- |
|
0.01 |
|
-- |
|
1.35 |
|
66.51 |
|
2.58% |
|
8.86% |
|
1.45% |
|
2.58% |
|
$0.24 |
|
$-0.06 |
|
|
Operating Cash Flow per Share |
$-0.06 |